NEUMORA THERAPEUTICS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-07-09: Study NCT06546995; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2024-05-13: Study NCT06429722; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2023-12-21: Study NCT06058039; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2023-12-20: Study NCT06058013; Company role Lead sponsor; Phase Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-07-09 | NCT06546995 Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease | Lead sponsor | Phase 1 | Completed | Alzheimer's Disease; Healthy Elderly | 87 | 2025-11-19 |
| 2024-05-13 | NCT06429722 To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder. | Lead sponsor | Phase 2 | Completed | Major Depressive Episode Associated With Bipolar II Disorder | 18 | 2025-05-30 |
| 2023-12-21 | NCT06058039 Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder | Lead sponsor | Phase 3 | Completed | Major Depressive Disorder | 422 | 2026-06-11 |
| 2023-12-20 | NCT06058013 Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Lead sponsor | Phase 3 | Completed | Major Depressive Disorder | 430 | 2026-06-17 |
| 2023-11-10 | NCT06029439 Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Lead sponsor | Phase 3 | Terminated | Major Depressive Disorder | 904 | 2026-08-17 |
| 2023-09-20 | NCT06029426 Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Lead sponsor | Phase 3 | Completed | Major Depressive Disorder | 383 | 2025-01-15 |
| 2020-01-03 | NCT04221230 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo | Lead sponsor | Phase 2 | Completed Results posted | Major Depressive Disorder | 204 | 2022-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |